{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=56&state=Minnesota",
    "query": {
      "state": "Minnesota",
      "city": "Minneapolis",
      "page": 56
    },
    "page_size": 10
  },
  "pagination": {
    "page": 56,
    "page_size": 10,
    "total_count": 7879,
    "total_pages": 788,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=57&state=Minnesota&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=55&state=Minnesota&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:23:27.853Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07788755",
      "title": "NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Cognitive Impairment",
        "Visual Impairment"
      ],
      "interventions": [
        {
          "name": "Perceptual Discrimination Training",
          "type": "DEVICE"
        },
        {
          "name": "Cognitive Control Training",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 168,
      "start_date": "2026-11-30",
      "completion_date": "2031-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07788755"
    },
    {
      "nct_id": "NCT04628585",
      "title": "Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "53 Years",
        "sex": "ALL",
        "summary": "2 Years to 53 Years"
      },
      "enrollment_count": 85,
      "start_date": "2020-10-21",
      "completion_date": "2038-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Oakland, California • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628585"
    },
    {
      "nct_id": "NCT03635515",
      "title": "Occurrence of Post-op Pain Following Gentlewave",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Root Canal Infection",
        "Endodontic Disease",
        "Endodontic Inflammation",
        "Post-Operative Pain"
      ],
      "interventions": [
        {
          "name": "Gentlewave",
          "type": "DEVICE"
        },
        {
          "name": "Standard Endodontic Protocol",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2018-09-01",
      "completion_date": "2021-07-31",
      "has_results": true,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635515"
    },
    {
      "nct_id": "NCT04395508",
      "title": "An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • San Francisco, California • Stanford, California + 9 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04395508"
    },
    {
      "nct_id": "NCT02709265",
      "title": "Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "amikacin/fosfomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardeas Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-04",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709265"
    },
    {
      "nct_id": "NCT06819007",
      "title": "Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 582,
      "start_date": "2025-03-19",
      "completion_date": "2032-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 33,
      "location_summary": "Burbank, California • La Jolla, California • Palo Alto, California + 26 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06819007"
    },
    {
      "nct_id": "NCT00467051",
      "title": "Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Extracranial Germ Cell Tumor",
        "Childhood Extragonadal Malignant Germ Cell Tumor",
        "Childhood Malignant Ovarian Germ Cell Tumor",
        "Childhood Malignant Testicular Germ Cell Tumor",
        "Ovarian Choriocarcinoma",
        "Ovarian Embryonal Carcinoma",
        "Ovarian Yolk Sac Tumor",
        "Recurrent Childhood Malignant Germ Cell Tumor",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Ovarian Germ Cell Tumor",
        "Testicular Choriocarcinoma",
        "Testicular Embryonal Carcinoma",
        "Testicular Mixed Choriocarcinoma and Embryonal Carcinoma",
        "Testicular Mixed Choriocarcinoma and Yolk Sac Tumor",
        "Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor",
        "Testicular Yolk Sac Tumor"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-11-05",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 85,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467051"
    },
    {
      "nct_id": "NCT01043939",
      "title": "Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Purple Grape Juice",
          "type": "OTHER"
        },
        {
          "name": "Apple Juice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "10 Years to 30 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-11",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-12-31",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01043939"
    },
    {
      "nct_id": "NCT05444257",
      "title": "A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-121/TEZ/D-IVA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 822,
      "start_date": "2022-11-08",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05444257"
    },
    {
      "nct_id": "NCT04062630",
      "title": "SI Joint Stabilization in Long Fusion to the Pelvis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sacroiliac Joint Disruption",
        "Scoliosis Lumbar Region"
      ],
      "interventions": [
        {
          "name": "iFuse 3-D in Bedrock Configuration",
          "type": "DEVICE"
        },
        {
          "name": "Multilevel Lumbar Fusion surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "SI-BONE, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 213,
      "start_date": "2020-05-20",
      "completion_date": "2025-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-11-19T10:23:27.853Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04062630"
    }
  ]
}